MRG008 / Lepu Biopharma - LARVOL DELTA

MRG008: A novel EGFR and 5T4 bispecific antibody-drug conjugate (ADC) with potent antitumor activity in preclinical studies (AACR 2026) - "EGFR (also known as HER1) is an epidermal growth factor receptor with tyrosine kinase activity implicated in both tumorigenesis and tumor progression, and its validity as a therapeutic target for ADC has been clinically confirmed, as exemplified by our approved drug MRG003. MRG008 is a promising dual-targeted ADC with potent anti-tumor efficacy for the treatment of NSCLC. These preclinical findings provide a strong rationale for advancing MRG008 into IND-enabling and clinical studies."

ADC • Bispecific • Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR • TPBG